Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2567-2571

  Gonzalez Parra, Emilio ^a   Gonzalez Casaus, Maria Luisa ^b   Galán, Antonio ^c   Martinez Calero, Alberto ^d   Navas, Victor ^e   Rodriguez, Mariano ^f   Ortiz, Alberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d Department of Nephrology   (Spain)

^e Shire Pharmaceuticals Iberia   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

chronic kidney disease; FGF 23; lanthanum; phosphate

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

AGED; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; LONGITUDINAL STUDIES; MALE; PHOSPHORUS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 79961052017     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr144     Document Type: Article

References (34)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risk of death cardiovascular events and hospitalization. N Engl J Med 2004;351:1296-1305
2. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17
3. Phelan PJ, O'Kelly, Walshe JJ et al. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail 2008;30:423-429 (Pubitemid 351868691)
4. Ayús JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005;16:2778-2788
5. Schwartz S, Trivedi BK, Kalantar-Zadeh K et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006;1:825-831
6. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528 (Pubitemid 41725150)
7. Isakova T, Gutierrez O, Wolf M. A blueprint for randomized trials targeting phosphorous metabolism in chronic kidney disease. Kidney Int 2009;76:705-716
8. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-2633 (Pubitemid 41532599)
9. Rodriguez M, Felsenfeld AJ. PTH, FGF23 and early CKD. Nephrol Dial Tranplant 2008;23:3391-3393
10. Ix JH, Shlipak MG, Wassel CL et al. Fibroblast growth factor-23 and early decrements in kidney function: the heart and Soul Study. Nephrol Dial Transplant 2010;25:993-997
11. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor-23 predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMMKD) Study. J Am Soc Nephrol 2007;18:613-620
12. Isakova T, Gutierrez O, Shah A et al. Postpandrial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008;19:615-623 (Pubitemid 351355405)
13. Craver L, Marco MP, Martinez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 achievement of K/DOQI target ranges. Nephrol Dial Tranplant 2007;22:1171-1176 (Pubitemid 46523434)
14. Gutierrez OM, Mannstandt M, Isakova T et al. Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592
15. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-396
16. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005;100:c8-c19 (Pubitemid 40674602)
17. Sprague SM, Abboud H, Qiu P et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009;4:178-185
18. De Lorenzo A, Noce A, Bigioni M et al. The effects of Italian Mediterranean organic diet (IMOD) on health status. Curr Pharm Des 2010;16:814-824
19. Oliveira RB, Cancela A L E, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy. Clin J Am Soc Nephrol 2010;5:286-291
20. Isakova T, Gutiérrez OM, Smith K et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011;26:584-591
21. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009;337:116-122
22. Gutierrez O, Januzzi J, Isakova T et al. Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-2552
23. Seiler S, Reichart B, Roth D et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010;25:3983-3989
24. Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640-648
25. Rodriguez M, Martin Malo A, Martinez M et al. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int 1991;40:1055-1062
26. Felsenfeld AJ, Rodriguez M. Phosphorus, calcium regulation and secondary hyperparathyroidism: an attempt to integrate a historical and modern perspective. J Am Soc Nephrol 1999;10:878-890 (Pubitemid 29149540)
27. Somerville PJ, Kaye M. Evidence that resistance to the calcemic action of parathyroid hormone in rats with acute uremia is caused by phosphate retention. Kidney Int 1979;16:552-560 (Pubitemid 10163670)
28. Pool L, Martins PT, Robinson AG et al. A balance study comparing the absorption of dietary phosphorus with lanthanum carbonate or sevelamer carbonate in healthy adult volunteers. Nephrol Dial Transplant 2010;3:388
29. He X, Zhang ZY, Feng LX et al. Effects of acute lanthanum exposure on calcium absorption in rats. J Radioanal Nucl Chem 2007;272:557-559 (Pubitemid 46686076)
30. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-4008 (Pubitemid 350224109)
31. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010;21:1125-1135
32. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010;77:211-218
33. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010;77:292-298
34. Krajisnik T, Olauson H, Mirza MA et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010;78:1024-1032